CJ Bioscience, Inc. (KOSDAQ:311690)

Market Cap	129.35B
Revenue (ttm)	3.38B
Net Income (ttm)	-31.59B
Shares Out	13.07M
EPS (ttm)	-3,078.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,275
Average Volume	106,598
Open	9,810
Previous Close	9,860
Day's Range	9,800 - 10,150
52-Week Range	8,250 - 18,800
Beta	0.69
RSI	48.72
Earnings Date	Aug 14, 2025

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics a...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 311690

Financial Performance

In 2024, CJ Bioscience's revenue was 3.47 billion, a decrease of -37.82% compared to the previous year's 5.58 billion. Losses were -32.84 billion, 43.3% more than in 2023.